RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Ironshore Pharmaceuticals Inc. (“Ironshore”), a wholly owned subsidiary of Highland Therapeutics Inc. and a leader in the commercialization of novel ...

Methylphenidate hydrochloride extended-release tablets should be given cautiously to patients with a history of drug dependence or alcoholism. Chronic abusive use can lead to marked tolerance and ...

Extended-Release Is Now Chewable: First and Only Long-Acting Chewable Methylphenidate Treatment for Attention Deficit Hyperactivity Disorder (ADHD) in patients ages 6 years old and above Monday, ...

STAMFORD, Conn.--(BUSINESS WIRE)--Adlon Therapeutics L.P., a subsidiary of Purdue Pharma L.P., announced that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application ...

ALPHARETTA, Ga., Aug. 19, 2025 /PRNewswire/ -- Alora Pharmaceuticals, LLC, the parent company of Vertical Pharmaceuticals, LLC, a leading pharmaceutical company committed to advancing access to ...

The Food and Drug Administration (FDA) has expressed concerns about the therapeutic equivalence of two generic versions of Concerta (methylphenidate HCl extended-release; Janssen) tablets indicated ...

(RTTNews) - Dr. Reddy's Laboratories Ltd. (RDY), an integrated pharmaceutical company, announced the launch of Methylphenidate Hydrochloride Extended-Release Tablets USP, 18 mg, 27 mg, 36 mg and 54 mg ...

Medication offers relief from 'home to homework' 25 FEBRUARY 2002 – London, UK -- A new, once-daily treatment for attention deficit hyperactivity disorder (ADHD), Concerta® XL (methylphenidate HCl), ...

Mallinckrodt announced the launch of Methylphenidate HCl Extended-Release (ER) Tablets, the generic version of Janssen‘s Concerta. Concerta is a stimulant indicated for attention deficit hyperactivity ...

Although methylphenidate hydrochloride (MPH) is a first-line treatment for children with attention-deficit hyperactivity disorder (ADHD), the non-response rate is 30%. Our aim was to develop a ...